At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 36 enrolled / 36 target
Drug / intervention
omidubicelbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
In Brief
A Phase 3 clinical trial evaluating omidubicel for Hematological Malignancies. Completed, enrolled 36 participants across 6 sites.
Signals
Enrolling slower than its timeline implies
Detailed Summary
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematological Malignancies
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartJul 2020
Primary CompletionMay 2025
TodayJul 2026
First PostedFeb 7, 2020
Enrollment StartJul 8, 2020
Primary CompletionMay 8, 2025
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 6.4 years ago
Arms & Interventions
omidubicelexperimental
Received omidubicel
Biological: omidubicel
Interventions
omidubicelbiological
hematopoietic stem cell transplant